We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exelixis Starts Study on Cabometyx Combo in Kidney Cancer
Read MoreHide Full Article
Exelixis, Inc. (EXEL - Free Report) announced the initiation of CONTACT-03, a global phase III pivotal study of Cabometyx (cabozantinib) in combination with Roche AG’s (RHHBY - Free Report) Tecentriq (atezolizumab). The study will be conducted in patients with inoperable, locally advanced or metastatic renal cell carcinoma (RCC), who progressed during or following the treatment with an immune checkpoint inhibitor as the immediate preceding therapy.
About 500 patients are expected to be enrolled in the study. In the study, the patients will be randomized 1:1 to the experimental arm of Cabometyx in combination with Tecentriq or the control arm of Cabometyxalone. The co-primary endpoints of the study are progression-free survival per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1, as assessed by independent review, and overall survival. Secondary endpoints include progression-free survival, objective response rate and duration of response, as assessed by the investigators.
The CONTACT-03 study is sponsored by Roche and co-funded by Exelixis. The study is the third of the three phase III pivotal studies that are part of a clinical collaboration with Roche. The other two studies are CONTACT-01 and CONTACT-02. The CONTACT-01 study deals with patients with metastatic non-small cell lung cancer (NSCLC), who have been previously treated with an immune checkpoint inhibitor and platinum-containing chemotherapy. CONTACT-02 focuses on patients with metastatic castration-resistant prostate cancer (CRPC), who have been previously treated with one novel hormonal therapy. Both these studies were initiated in June 2020.
Cabometyx tablets are already approved in the United States for the treatment of advanced RCC and hepatocellular carcinoma (HCC), who have been previously treated with Bayer's (BAYRY - Free Report) Nexavar.
The company’s shares have surged 45.3% year to date compared with the industry’s growth of 12.6%.
However, competition is stiff from the recently approved combination therapies for RCC. The FDA has approved Merck’s (MRK - Free Report) Keytruda in combination with Inlyta for the first-line treatment of patients with advanced RCC.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Image: Bigstock
Exelixis Starts Study on Cabometyx Combo in Kidney Cancer
Exelixis, Inc. (EXEL - Free Report) announced the initiation of CONTACT-03, a global phase III pivotal study of Cabometyx (cabozantinib) in combination with Roche AG’s (RHHBY - Free Report) Tecentriq (atezolizumab). The study will be conducted in patients with inoperable, locally advanced or metastatic renal cell carcinoma (RCC), who progressed during or following the treatment with an immune checkpoint inhibitor as the immediate preceding therapy.
About 500 patients are expected to be enrolled in the study. In the study, the patients will be randomized 1:1 to the experimental arm of Cabometyx in combination with Tecentriq or the control arm of Cabometyxalone. The co-primary endpoints of the study are progression-free survival per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1, as assessed by independent review, and overall survival. Secondary endpoints include progression-free survival, objective response rate and duration of response, as assessed by the investigators.
The CONTACT-03 study is sponsored by Roche and co-funded by Exelixis. The study is the third of the three phase III pivotal studies that are part of a clinical collaboration with Roche. The other two studies are CONTACT-01 and CONTACT-02. The CONTACT-01 study deals with patients with metastatic non-small cell lung cancer (NSCLC), who have been previously treated with an immune checkpoint inhibitor and platinum-containing chemotherapy. CONTACT-02 focuses on patients with metastatic castration-resistant prostate cancer (CRPC), who have been previously treated with one novel hormonal therapy. Both these studies were initiated in June 2020.
Cabometyx tablets are already approved in the United States for the treatment of advanced RCC and hepatocellular carcinoma (HCC), who have been previously treated with Bayer's (BAYRY - Free Report) Nexavar.
The company’s shares have surged 45.3% year to date compared with the industry’s growth of 12.6%.
However, competition is stiff from the recently approved combination therapies for RCC. The FDA has approved Merck’s (MRK - Free Report) Keytruda in combination with Inlyta for the first-line treatment of patients with advanced RCC.
Exelixis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Exelixis, Inc. Price
Exelixis, Inc. price | Exelixis, Inc. Quote
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>